Lantern Pharma Inc.

Historical 13F Holders

Reported Value, Excluding Options

Total Filings

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 51654W101 since 12/18/2024, largest first.

Filer	% of Class	Shares	Form	Filed
Empery Asset Management, LP 13G	10.0%	1,322,551	13G	8/4/2026 Event 6/30/2026
Empery Asset Management, LP	10.0%	1,322,551
Ryan M. Lane	10.0%	1,322,551
Thomas A. Satterfield, Jr. 13G/A	7.6%	975,000	13G/A	7/23/2026 Event 6/30/2026
Under 5%, checked the "5 percent or less" box, or amended by a later filing (1)
Bios Equity Partners, LP 13D/A	4.5%	571,305	13D/A	5/15/2026 Event 5/15/2026
Bios Advisors GP, LLC	4.5%	571,305
Aaron G.L. Fletcher	4.5%	571,305
Cavu Management, LP	4.5%	571,305
Cavu Advisors, LLC	4.5%	571,305
Leslie W. Kreis	4.5%	571,305
Bios Equity Partners, LP	2.1%	266,621
Bios Equity Partners II, LP	2.4%	304,684
Bios Capital Management, LP	4.5%	571,305
Bios Fund II NT, LP	0.2%	28,324
Bios Fund II QP, LP	1.7%	211,566
Bios Fund II, LP	0.5%	64,794
BP Directors, LP	0.2%	26,093
Bios Fund I QP, LP	0.7%	88,769
Bios Fund I, LP	1.2%	151,759

Period	Filings	Shares, Excl. Options	Value, Excl. Options	Options Value
2026 Q3	1	8.50 k	$8.59 k	$0
2026 Q2	39	2.88 M	$12.0 M	$0
2026 Q1	33	2.10 M	$2.87 M	$0
2025 Q4	35	2.28 M	$6.91 M	$72.7 k
2025 Q3	32	2.28 M	$9.93 M	$80.0 k
2025 Q2	37	2.25 M	$7.11 M	$51.8 k
2025 Q1	35	2.43 M	$8.62 M	$65.1 k
2024 Q4	35	2.50 M	$8.00 M	$16.6 k
2024 Q3	34	1.34 M	$4.90 M	$168 k
2024 Q2	43	1.29 M	$6.01 M	$226 k
2024 Q1	41	1.11 M	$9.77 M	$1.29 M
2023 Q4	35	1.16 M	$4.95 M	$2.57 k
2023 Q3	30	1.15 M	$3.93 M	$30.7 k
2023 Q2	28	1.15 M	$6.50 M	$2.26 k
2023 Q1	24	1.08 M	$5.23 M	$38.2 k
2022 Q4	27	1.09 M	$5.56 M	$43.5 k
2022 Q3	30	1.44 M	$6.84 M	$283 k
2022 Q2	27	1.42 M	$8.06 M	$0
2022 Q1	26	1.45 M	$10.4 M	$0
2021 Q4	37	1.67 M	$13.2 M	$198 k
2021 Q3	26	1.40 M	$15.7 M	$0
2021 Q2	23	1.35 M	$19.7 M	$0
2021 Q1	26	1.40 M	$25.5 M	$325 k
2020 Q4	11	83.0 k	$1.60 M	$0
2020 Q3	13	160 k	$3.02 M	$0
2020 Q2	6	122 k	$1.55 M	$0